Lower ribavirin plasma concentrations in HCV/HIV-coinfected patients than in HCV-monoinfected patients despite similar dosage

Maarten J. Deenen; Clara T M M De Kanter; Anthonius S M Dofferhoff; Karin J T Grintjes-Huisman; Andre J A M Van Der Ven; Hanneke W H A Fleuren; Elizabeth H. Gisolf; Peter P. Koopmans; Joost P H Drenth; David M. Burger

doi:10.1097/FTD.0000000000000226

Lower ribavirin plasma concentrations in HCV/HIV-coinfected patients than in HCV-monoinfected patients despite similar dosage

Maarten J. Deenen
, Clara T M M De Kanter^*
, Anthonius S M Dofferhoff
, Karin J T Grintjes-Huisman
, Andre J A M Van Der Ven
, Hanneke W H A Fleuren
, Elizabeth H. Gisolf
, Peter P. Koopmans
, Joost P H Drenth
, David M. Burger

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Background: Hepatitis C virus (HCV)/HIV-coinfected patients respond worse to dual therapy with ribavirin (RBV)/peginterferon compared with HCV-monoinfected patients. Several trials found that lower RBV plasma concentrations are associated with impaired virological response rates. The aim of this study was to determine RBV plasma concentrations in a cohort of HCV-monoinfected and HCV/HIV-coinfected patients. Our hypothesis is that HCV/HIV- coinfected patients have lower RBV plasma concentrations, which may in part explain their inferior response to dual therapy. Methods: A retrospective cohort study was performed in chronic HCV-monoinfected and HCV/HIV-coinfected patients who received peginterferon and weight-based RBV. Plasma RBV concentrations were determined at weeks 4 and 12 by a validated highperformance liquid chromatography assay. RBV concentrations were compared between monoinfected and coinfected patients. We calculated the proportion of patients with a subtherapeutic RBV plasma concentration defined as

Original language	English
Pages (from-to)	751-755
Number of pages	5
Journal	Therapeutic Drug Monitoring
Volume	37
Issue number	6
DOIs	https://doi.org/10.1097/FTD.0000000000000226
Publication status	Published - 2015
Externally published	Yes

Keywords

Coinfection
Hepatitis C
HIV
Ribavirin
Therapeutic drug monitoring

Access to Document

10.1097/FTD.0000000000000226

Cite this

Deenen, M. J., De Kanter, C. T. M. M., Dofferhoff, A. S. M., Grintjes-Huisman, K. J. T., Van Der Ven, A. J. A. M., Fleuren, H. W. H. A., Gisolf, E. H., Koopmans, P. P., Drenth, J. P. H., & Burger, D. M. (2015). Lower ribavirin plasma concentrations in HCV/HIV-coinfected patients than in HCV-monoinfected patients despite similar dosage. Therapeutic Drug Monitoring, 37(6), 751-755. https://doi.org/10.1097/FTD.0000000000000226

@article{32f6fd8c74e9436dbc5a706981cd491a,

title = "Lower ribavirin plasma concentrations in HCV/HIV-coinfected patients than in HCV-monoinfected patients despite similar dosage",

abstract = "Background: Hepatitis C virus (HCV)/HIV-coinfected patients respond worse to dual therapy with ribavirin (RBV)/peginterferon compared with HCV-monoinfected patients. Several trials found that lower RBV plasma concentrations are associated with impaired virological response rates. The aim of this study was to determine RBV plasma concentrations in a cohort of HCV-monoinfected and HCV/HIV-coinfected patients. Our hypothesis is that HCV/HIV- coinfected patients have lower RBV plasma concentrations, which may in part explain their inferior response to dual therapy. Methods: A retrospective cohort study was performed in chronic HCV-monoinfected and HCV/HIV-coinfected patients who received peginterferon and weight-based RBV. Plasma RBV concentrations were determined at weeks 4 and 12 by a validated highperformance liquid chromatography assay. RBV concentrations were compared between monoinfected and coinfected patients. We calculated the proportion of patients with a subtherapeutic RBV plasma concentration defined as ",

keywords = "Coinfection, Hepatitis C, HIV, Ribavirin, Therapeutic drug monitoring",

author = "Deenen, \{Maarten J.\} and \{De Kanter\}, \{Clara T M M\} and Dofferhoff, \{Anthonius S M\} and Grintjes-Huisman, \{Karin J T\} and \{Van Der Ven\}, \{Andre J A M\} and Fleuren, \{Hanneke W H A\} and Gisolf, \{Elizabeth H.\} and Koopmans, \{Peter P.\} and Drenth, \{Joost P H\} and Burger, \{David M.\}",

year = "2015",

doi = "10.1097/FTD.0000000000000226",

language = "English",

volume = "37",

pages = "751--755",

journal = "Therapeutic Drug Monitoring",

issn = "0163-4356",

publisher = "Lippincott Williams \& Wilkins",

number = "6",

}

Deenen, MJ, De Kanter, CTMM, Dofferhoff, ASM, Grintjes-Huisman, KJT, Van Der Ven, AJAM, Fleuren, HWHA, Gisolf, EH, Koopmans, PP, Drenth, JPH & Burger, DM 2015, 'Lower ribavirin plasma concentrations in HCV/HIV-coinfected patients than in HCV-monoinfected patients despite similar dosage', Therapeutic Drug Monitoring, vol. 37, no. 6, pp. 751-755. https://doi.org/10.1097/FTD.0000000000000226

TY - JOUR

T1 - Lower ribavirin plasma concentrations in HCV/HIV-coinfected patients than in HCV-monoinfected patients despite similar dosage

AU - Deenen, Maarten J.

AU - De Kanter, Clara T M M

AU - Dofferhoff, Anthonius S M

AU - Grintjes-Huisman, Karin J T

AU - Van Der Ven, Andre J A M

AU - Fleuren, Hanneke W H A

AU - Gisolf, Elizabeth H.

AU - Koopmans, Peter P.

AU - Drenth, Joost P H

AU - Burger, David M.

PY - 2015

Y1 - 2015

N2 - Background: Hepatitis C virus (HCV)/HIV-coinfected patients respond worse to dual therapy with ribavirin (RBV)/peginterferon compared with HCV-monoinfected patients. Several trials found that lower RBV plasma concentrations are associated with impaired virological response rates. The aim of this study was to determine RBV plasma concentrations in a cohort of HCV-monoinfected and HCV/HIV-coinfected patients. Our hypothesis is that HCV/HIV- coinfected patients have lower RBV plasma concentrations, which may in part explain their inferior response to dual therapy. Methods: A retrospective cohort study was performed in chronic HCV-monoinfected and HCV/HIV-coinfected patients who received peginterferon and weight-based RBV. Plasma RBV concentrations were determined at weeks 4 and 12 by a validated highperformance liquid chromatography assay. RBV concentrations were compared between monoinfected and coinfected patients. We calculated the proportion of patients with a subtherapeutic RBV plasma concentration defined as

AB - Background: Hepatitis C virus (HCV)/HIV-coinfected patients respond worse to dual therapy with ribavirin (RBV)/peginterferon compared with HCV-monoinfected patients. Several trials found that lower RBV plasma concentrations are associated with impaired virological response rates. The aim of this study was to determine RBV plasma concentrations in a cohort of HCV-monoinfected and HCV/HIV-coinfected patients. Our hypothesis is that HCV/HIV- coinfected patients have lower RBV plasma concentrations, which may in part explain their inferior response to dual therapy. Methods: A retrospective cohort study was performed in chronic HCV-monoinfected and HCV/HIV-coinfected patients who received peginterferon and weight-based RBV. Plasma RBV concentrations were determined at weeks 4 and 12 by a validated highperformance liquid chromatography assay. RBV concentrations were compared between monoinfected and coinfected patients. We calculated the proportion of patients with a subtherapeutic RBV plasma concentration defined as

KW - Coinfection

KW - Hepatitis C

KW - HIV

KW - Ribavirin

KW - Therapeutic drug monitoring

UR - https://www.scopus.com/pages/publications/84947905944

U2 - 10.1097/FTD.0000000000000226

DO - 10.1097/FTD.0000000000000226

M3 - Article

C2 - 26102531

AN - SCOPUS:84947905944

SN - 0163-4356

VL - 37

SP - 751

EP - 755

JO - Therapeutic Drug Monitoring

JF - Therapeutic Drug Monitoring

IS - 6

ER -

Lower ribavirin plasma concentrations in HCV/HIV-coinfected patients than in HCV-monoinfected patients despite similar dosage

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this